Literature DB >> 20008176

Darwin and evolutionary tales in leukemia. The Ham-Wasserman Lecture.

Mel Greaves1.   

Abstract

All cancers evolve by a process of genetic diversification and "natural selection" akin to the process first described by Charles Darwin for species evolution. The evolutionary, natural history of childhood acute lymphoblastic leukemia (ALL) is almost entirely covert, clinically silent and well advanced by the point of diagnosis. It has, however, been possible to backtrack this process by molecular scrutiny of appropriate clinical samples: (i) leukemic clones in monozygotic twins that are either concordant or discordant for ALL; (ii) archived neonatal blood spots or Guthrie cards from individuals who later developed leukemia; and (iii) stored, viable cord blood cells. These studies indicate prenatal initiation of leukemia by chromosome translocation and gene fusion (or hyperdiploidy) and the post-natal acquisition of multiple, gene copy number alterations (CNAs), mostly deletions. The prenatal or first "hit" occurs very commonly, exceeding the clinical rate of ALL by some 100x and indicating a low rate of penetrance or evolutionary progression. The acquisition of the critical, secondary CNAs requires some Darwinian selective advantage to expand numbers of cells at risk, and the cytokine TGF beta is able to exercise this function. The clonal architecture of ALL has been investigated by single cell analysis with multicolor probes to mutant genes. The data reveal not a linear sequence of mutation acquisition with clonal succession but rather considerable complexity with a tree-like or branching structure of genetically distinct subclones very reminiscent of Darwin's original 1837 evolutionary divergence diagram. This evolutionary pattern has important implications for stem cells in ALL, for the origins of relapse and for therapeutic targeting.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008176     DOI: 10.1182/asheducation-2009.1.3

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  20 in total

1.  Cancer: drug-tolerant insurgents.

Authors:  Paul Workman; Jon Travers
Journal:  Nature       Date:  2010-04-08       Impact factor: 49.962

Review 2.  Somatic mosaicism: on the road to cancer.

Authors:  Luis C Fernández; Miguel Torres; Francisco X Real
Journal:  Nat Rev Cancer       Date:  2015-12-18       Impact factor: 60.716

3.  Where do the leukaemia relapses come from?

Authors:  Arndt Borkhardt
Journal:  J Mol Med (Berl)       Date:  2010-03       Impact factor: 4.599

4.  Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.

Authors:  Max Jan; Thomas M Snyder; M Ryan Corces-Zimmerman; Paresh Vyas; Irving L Weissman; Stephen R Quake; Ravindra Majeti
Journal:  Sci Transl Med       Date:  2012-08-29       Impact factor: 17.956

Review 5.  Clonal evolution of acute leukemia genomes.

Authors:  M Jan; R Majeti
Journal:  Oncogene       Date:  2012-02-20       Impact factor: 9.867

Review 6.  Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.

Authors:  Sarah K Tasian; Stephen P Hunger
Journal:  Br J Haematol       Date:  2016-12-16       Impact factor: 6.998

Review 7.  Childhood acute lymphoblastic leukemia: Integrating genomics into therapy.

Authors:  Sarah K Tasian; Mignon L Loh; Stephen P Hunger
Journal:  Cancer       Date:  2015-07-20       Impact factor: 6.860

Review 8.  Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia.

Authors:  T Bochtler; S Fröhling; A Krämer
Journal:  Leukemia       Date:  2015-02-12       Impact factor: 11.528

9.  Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression.

Authors:  J Lin; Y Goto; H Murata; K Sakaizawa; A Uchiyama; T Saida; M Takata
Journal:  Br J Cancer       Date:  2011-01-11       Impact factor: 7.640

10.  Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement.

Authors:  M Bardini; P S Woll; L Corral; S Luc; L Wittmann; Z Ma; L Lo Nigro; G Basso; A Biondi; G Cazzaniga; S E W Jacobsen
Journal:  Leukemia       Date:  2014-05-06       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.